Background: Viral flu is the predominant cause of hospitalization in young children, which invariably leads to enhanced morbidity and mortality in children in developing countries. Initial treatment of viral flu is based on presumptive diagnosis. Bedside testing is not common in clinical settings because of variable sensitivity and specificity of rapid tests in different settings. Methods: To address this issue, we evaluated the performance of Binax influenza A/B rapid testing kit against two robust molecular platforms (quantitative real-time polymerase chain reaction [qRT-PCR] and TaqMan array card [TAC]) in 24 nasopharyngeal (NP) swabs, collected from children under 5 years of age. Results: Binax was found to be less sensitive (56%), but 100% specific compared to qRT-PCR (100%) and TAC (>100%). Using TAC cards, 75% of samples were found to be coinfected with other bacterial and viral targets. Conclusion: Binax flu is suitable for bedside testing in clinical and community settings. The negative results of Binax should be interpreted with caution and confirmed by rapid molecular tests. 
IntroductIon
Viral influenza is the leading cause of deaths among children in developing countries. It is most common cause of admission of infants in emergency rooms for the treatment of seasonal flu. [1] Continuous evolution of new viral strains renders previous vaccines ineffective. Early diagnosis facilitates the initiation of antiviral treatment. [2, 3] This, in turn, reduces risk of transmission, [4] unnecessary usage of antibiotic, and length of hospital stay. [5] Molecular diagnostic tests are accurate, albeit not suitable as point-of-care test (POC). Rapid test is suitable for bedside testing; it requires a high viral load for positivity. [6] This study evaluated the performance of ICT-BinaxNOW kit (Alere Binax, Portland, ME), against quantitative real-time polymerase chain reaction (qRT-PCR) (CDC Ref. # I-007-05, Version 2009) and TaqMan array card (TAC) assay (Applied Biosystems, Foster City, CA) for influenza A and B viral testing in children less than 5 years of age. BinaxNOW kit is an in vitro immunochromatographic assay technique, used for the qualitative detection of influenza A and B nucleoprotein antigens in nasopharyngeal (NP) swab/wash/aspirate specimens. Within available molecular platforms, TAC is proving to be a valuable tool for multiple pathogen detection.
It is a 384-well microfluidic array comprising of precoated/ customized dried-down primers and probes as a singleplex qPCR reaction, used for simultaneous detection of up to 100 targets from a single specimen. It has been employed and evaluated previously for the identification of respiratory pathogens, enteropathogens, [7] and biothreat agents. [8] The clinical application of TAC is limited for bedside testing as it demands high technical expertise and infrastructure. In this study, we confirmed a low but invariable sensitivity of Binax from both clinical and community samples compared to high throughput and robust molecular tests of q-RT PCR and TAC assay.
Methods
Study samples (n = 24) were obtained from two study cohorts: Aetiology of Neonatal Infection in South Asia (ANISA) [8] In a 100 µL reaction, 50 µL Quanta master mix (VWR, USA) and 50 µL of TNA were used, the card was spin at 1200 rpm for 1 min each (Thermo Fisher Scientific, Germany), card was sealed with the help of array card stacker sealer (Applied Biosystems, USA), and the upper portion of the card was trimmed and ran on ViiA7 RTPCR system (Applied Biosystems, USA). The cycling condition was 45°C for 10 min, 94°C for 10 min, followed by 45 cycles of 94°C for 30 s, and 60°C for 1 min. The cutoff for positive test was any cycle threshold (Ct) value before 40 cycles and appearance of S-shaped sigmoidal curve [ Figure 1 ]. The TAC format was customized as per ANISA protocol. [8] Supplementary, Figure 2 illustrates the layout of TAC.
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results
Of 24 NP/OP tested, Binax had 37.5% (9/24) positive and 62.5% (15/24) negative test. Of 37.5% positive test, 29% were positive for influenza A and 8.3% positive for influenza B. Compared to Binax, qRT-PCR was positive for 66% (16/24) of test samples; of these, 42% and 25% were positive for influenza A and influenza B, respectively [Supplementary Table 1] . On the whole, qRT-PCR detected additional 7 samples that were missed by Binax test. The mean Ct value was 29.79 ± 5.3 (range = 23.45-40.9). TAC assay found to be more sensitive compared to qRT-PCR and detected three additional samples that were missed by qRT-PCR. In TAC assay, 50% (12/24) samples were positive for influenza A and 29% (7/24) were positive for influenza B. The combined sensitivity of Binax for both influenza A and B was 56% and specificity was 100%, keeping qRT-PCR as a gold standard. The sensitivity for influenza A was 70% (95% confidence interval: 34.75-93.33) and influenza B was 33% (95% CI: 4.33-77.72).
The combine sensitivity of TAC was >100% compared to qRT-PCR for both influenza A and influenza B. qRT-PCR was 30.25 compared to 23.91 of TAC (paired t-test; P = 0.017). This shows higher sensitivity of the TAC assay for sample with low viral load [ Figure 2 ].
The unique feature of TAC assay is a multiple pathogen detection along with influenza A and B target [ Figure 3 ]. Among bacterial targets, Streptococcus pneumoniae was the most common (37%) in all age groups followed by Klebsiella pneumoniae (20.8%). Among viral targets, respiratory syncytial virus, enterovirus, rhinovirus, and cytomegalovirus (CMV) were mostly present in younger children while rubella virus, rhinovirus, and CMV were the most common viral targets in neonates and infants along with influenza A/B [ Table 2 ]. In five influenza A/B-negative samples, TAC assay was able to detect rubella, rhinovirus, and S. pneumoniae as additional pathogenic targets in neonates [ Table 2 ].
dIscussIon
We compared the performance of three diagnostic platforms for the detection of influenza A and B in children with respiratory symptoms. In addition, we detected viral and bacterial coinfection other than influenza A/B using a highly sensitive TAC assay.
Although Binax allows prompt initiation of antiviral therapy that limits the injudicious use of antibiotics in viral influenza, the lower detection limit of the test is also problematic in case of lower viral load. Such rapid tests are useful in surveillance and POC testing in pandemic situations. The downside of rapid diagnostics test is its lower sensitivity and greater false negativity rate (~44%) as documented by other studies. [9] Results showed a higher specificity (100%) but lower sensitivity (56%) of Binax when compared to molecular methods. Moderate false-negative rate of Binax may lead to incorrect diagnosis and cause delay in appropriate therapy. [10] These findings are comparable to other studies that have demonstrated combined sensitivity of Binax ranging from 11.1% to 60.3% and specificity ranging from 93.6% to 100.0%, using qRT-PCR (as a gold standard method). [11] As recommended by the CDC, results from rapid tests should always be interpreted in the broader context of the circulating influenza strains, pandemicity, clinical suspicion, severity of illness, and risk for complications due to superimposed bacterial infection. Negative results should be further evaluated with more sensitive testing. [12] An interesting finding in our study was the predominance of S. pneumoniae and K. pneumoniae coinfection in children with and without influenza. The dual infection is the main cause of mortality as reported in the 2009 H1N1 pandemic. [13] In this context, TAC platform has application in the diagnosis of flu infections in pandemic areas with high risk of dual bacterial and viral infections. While TAC has been used quite extensively for the detection of diarrheal pathogens in multicenter studies, [7] it also showed a comparable sensitivity of TAC with qRT-PCR for enteropathogen detection. In a validation study, TAC assay showed a sensitivity ranging between 92% and 100% for influenza A/B. The sensitivity for other respiratory pathogen was lower compared to individual RTPCR. [14] Despite its limited use as POC test, TAC assay may be used as complimentary test to confirm the presence of coinfection in complicated cases of pneumonia. High-throughput feature and higher sensitivity of TAC assay are suitable for diagnostic laboratories apt with trained staff and equipment facility.
conclusIon
In our study, Binax demonstrated low-to-moderate sensitivity for influenza A and B, which is comparable to previously reported results in meta-analysis with pooled sensitivity of 68%-81%. [15] It still remains as a choice of test for rapid diagnosis and POC testing, but negative results should be interpreted with caution and further testing is recommended as per CDC guidelines. 
